Skip to main content
Premium Trial:

Request an Annual Quote

Perlegen Announces Two More Pharma Collaborations

NEW YORK, Dec. 20-Perlegen, the Affymetrix spin-off, announced two pharmaceutical company deals in pharmacogenomics and disease-related SNP research.


The company said today that it has struck a deal with Pfizer to study the genetics of cardiovascular disease, using its chip-based genotyping technique to identify disease-associated genetic variations.


Further details of the collaboration, including financial information, were not disclosed.


On Dec. 18, Perlegen said it would collaborate with Eli Lilly to identify disease markers using its SNP portfolio and its chip-based whole genome screening technology. In this deal, Perlegen will get research funding, milestone payments,  royalties, and an equity investment from Lilly. Perlegen also retains some rights to develop products based on the research.


It has been a busy week for Perlegen: Yesterday, the company said it had struck a similar dealwith Bristol-Myers Squibb.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.